• Search

Search in Site

PharmaDeviceNews | Pharma and Medical Device Industry News PharmaDeviceNews.com
  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
```
Home»Posts tagged with»ADAP Crisis Task Force

Can Merck’s IDVYNSO agreement widen HIV treatment access across state programmes?

By Pallavi Madhiraju on June 30, 2026   Pharma & Biotech  

Can Merck’s IDVYNSO agreement widen HIV treatment access across state programmes?

See how Merck’s IDVYNSO ADAP agreement could widen HIV treatment access while pricing, formularies and clinical limits shape uptake.

Recent Posts

  • Samsung Bioepis SB27 meets Phase 3 endpoint as Keytruda biosimilar competition accelerates
  • Covista links scholarships, clinical training and employment in Advocate Health nursing deal
  • United Therapeutics wins FDA approval for LungFX, but pivotal survival data may shape uptake
  • Enhertu wins EU tumor-agnostic approval, but HER2 testing will decide its real impact
  • Can Merck’s IDVYNSO agreement widen HIV treatment access across state programmes?
  • Natera and Aveta Biomics bring Signatera into APG-157 Phase 3 head and neck cancer trial
  • FDA expands Skyrizi to children as AbbVie introduces weight-based 55 mg dose
  • Sobi’s NASP FDA setback turns uncontrolled gout opportunity into a manufacturing test
  • Can IMAAVY’s sustained control data reshape earlier treatment of generalized myasthenia gravis?
  • Could Larimar be closer to changing the Friedreich’s ataxia treatment landscape?
  • Nippon Shinyaku backs EXG-7001 as full-length dystrophin mRNA strategy enters Duchenne race
  • Can Anixa’s breast cancer vaccine and lira-cel CAR-T therapy translate early immune signals into clinical benefit?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes